⬡NOVALYTELABS
COMPOUND REFERENCE

The research compound in Victoza®

Victoza® is a type 2 diabetes medicine from Novo Nordisk. Its active compound is Liraglutide — which is what this catalogue supplies, as a research material.

This is not Victoza®, and NOVALYTE LABS has no affiliation with Novo Nordisk. We supply the compound Liraglutide for laboratory research only — not for human consumption, diagnostic, therapeutic or veterinary use. Victoza® is a trademark of Novo Nordisk, referenced here only to identify the compound.

Victoza is the brand under which liraglutide is marketed for type 2 diabetes. The same compound is sold as Saxenda for weight management.

It was among the first GLP-1 agonists engineered for extended action through fatty-acid acylation, a design principle later taken further by semaglutide.

The compound is listed here as a research material, not as the branded medicine.

Liraglutide in this catalogue

NOVALYTELiraglutide0.6mg × 5 pensPrefilled injection penStore 2–8 °CRESEARCH USE ONLY
Metabolic ResearchLiraglutide

0.6mg × 5 pens

€299.90€194.90
View compound

How Liraglutide is supplied here

Everything below describes the research material in this catalogue, not the medicine. Liraglutide is stocked in 3 presentations, so the figures below are for the base one.

CompoundLiraglutide
Presentation0.6mg × 5 pens
Dosage options0.6mg × 5 pens · 1.8mg × 5 pens · 3mg × 5 pens
Research categoryMetabolic Research
Batch COACertificate supplied with order
AvailabilityIn stock
Intended useLaboratory research only — not for human or veterinary use

Common questions

What is the active compound in Victoza?

Liraglutide. Victoza is a registered trademark of Novo Nordisk, approved for type 2 diabetes.

Is this Victoza?

No. NOVALYTE LABS supplies Liraglutide as a research material with batch documentation. It is not Victoza, it is not a medicine, it is not supplied for human use, and there is no affiliation with Novo Nordisk.

Why is Liraglutide sold under more than one brand?

Because a brand is tied to an approved indication rather than to the molecule. Liraglutide is marketed as Victoza and also as Saxenda — same compound, different approvals.

Other brands using Liraglutide

The same compound is marketed under more than one brand, usually because each brand carries a different approved indication.